Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration

Cancer Research

Volumn 61, Issue 3, 2001, Pages 842-847

  Yu, John S ^a,b   Wheeler, Christopher J ^a   Zeltzer, Paul M ^a,b   Ying, Han ^a   Finger, Divina N ^a   Lee, Paul K ^a   Yong, William H ^a   Incardona, Francesca ^a   Thompson, Reid C ^a,b   Riedinger, Mary S ^a   Zhang, Wenxuan ^a   Prins, Robert M ^a   Black, Keith L ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; VACCINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DENDRITIC CELL; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

ADULT; AGED; ANTIGENS, NEOPLASM; ASTROCYTOMA; BRAIN NEOPLASMS; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0035107548     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
2. T cell costimulatory molecules BT-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in culture
3. Disseminating tumor cells and their interactions with leukocytes visualized in the brain
4. Peptide and protein antigens require distinct antigen-presenting cell subjects for the priming of CD4+ T cells
5. Role of dendritic cells in the priming of CD4+ lymphocytes to peptide antigen in vivo
6. The dendritic cell system and its role in immunogenicity
7. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induced antitumor immunity against central nervous system tumors
8. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-γ treatment
9. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens
10. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
11. A simple assay for DNA fragmentation and cell death
12. Immunotherapy of malignant brain tumors in children and adults
13. Molecular detection of tumor-association antigens shared by human cutaneous melanomas and gliomas
14. Detection of MAGE-1 tumor antigen in brain tumor
15. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
16. Vaccination of melanoma patients with peptide- or tumor lysatepulsed dendritic cells
17. Evaluation of Phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides
18. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
19. Failure of adjuvant immunotherapy to prevent central nervous system metastases in malignant melanoma patients
20. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators
21. Vaccination for experimental gliomas using granulocyte-macrophage colony-stimulating factor-transduced tumor cells
22. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune response in vivo
23. Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue
24. Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials
25. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system